跳至主要内容
临床试验/CTRI/2023/05/052416
CTRI/2023/05/052416尚未招募3 期

A RANDOMIZED CONTROLLED CLINICAL STUDY ON DADIMADI AVALEHA AS PALLIATIVE CARE IN CHILDHOOD SICKLE CELL DISEASE

Dr Ragini Patidar0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Pre diagnosed cases of positive sickling test will be taken only
  • Age between 3 years to 16 years irrespective of gender caste religion
  • Patient with sign and symptoms of sickle cell anaemia
  • Hb >6.5% and < 11.5 %
  • Hb electrophoresis reporting % of Hb S >10 gm%
  • Serum Bilirubin less than 3 mg/d

排除标准

  • Age less than 3 years and greater than 16 years
  • Patients with known case of Hepatic Renal Dysfunction Chronic Cardiac Dysfunction
  • SCA associated with other known diseases like Diabetes Mellitust Thalasemia and Hypertension
  • Hb < 6.5 gm% and >11.5 gm%
  • Serum bilirubin level more than 3 mg/dL
  • Known case of other Haemoglobinopathies and Haematological diseases other than Sickle cell anaemia like G6PD deficiency Thalassemia Sickle cell beta thalassemia

研究者

发起方
Dr Ragini Patidar

相似试验

Dadimadi Avaleha for childhood Sickle cell disease | 临床试验